SCHEMBL3671890

SCHEMBL3671890

CNCC(=O)N(C)c1n[nH]c2ccc(-c3cn(C[Si](C)(C)C)nn3)cc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 19/20 0.52
HIPK2 Q9H2X6 11/20 0.49
CDK2 P24941 11/20 0.49
ROCK2 O75116 9/20 0.49
DAPK3 O43293 9/20 0.49
CDK5 Q00535 9/20 0.49
DYRK1A Q13627 9/20 0.49
PRKACA P17612 8/20 0.49
CLK2 P49760 8/20 0.49
MAP4K5 Q9Y4K4 7/20 0.49
PIM1 P11309 7/20 0.49
GSK3B P49841 6/20 0.49
AURKB Q96GD4 5/20 0.49
CLK4 Q9HAZ1 5/20 0.49
MAPK13 O15264 4/20 0.49
CDK1 P06493 4/20 0.49
MAPK1 P28482 4/20 0.49
CSNK1D P48730 4/20 0.49
MAPK12 P53778 4/20 0.49
CSNK2A1 P68400 4/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3669100 0.87 CDC7 (0.53) CDC7HIPK2CDK2ROCK2DAPK3
SCHEMBL4295544 0.84 CDC7 (0.56) CDC7HIPK2CDK2ROCK2DAPK3
SCHEMBL4291662 0.84 CDC7 (0.46) CDC7HIPK2CDK2ROCK2DAPK3
SCHEMBL3667833 0.79 CDC7 (0.38) CDC7HIPK2CDK2ROCK2DAPK3
SCHEMBL3671888 0.77 CDC7 (0.76) CDC7HIPK2CDK2ROCK2DAPK3
SCHEMBL3675189 0.76 DYRK1A (0.52) ROCK2DYRK1APRKACAPIM1GSK3B
SCHEMBL3665797 0.76 GSK3B (0.54) DYRK1AGSK3B
SCHEMBL3671681 0.75 JAK2 (0.50) DYRK1APIM1GSK3BJAK2MAPK8
SCHEMBL3670131 0.75 DYRK1A (0.51) DYRK1ACLK2GSK3BCDK7
SCHEMBL3668981 0.74 DYRK1A (0.52) DYRK1APIM1GSK3BJAK2FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885HIPK2 256/4885CDK2 65/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885HIPK2 256/4885CDK2 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.